DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20171034

A comparative study of oral, sublingual and vaginal route of misoprostol as cervical ripening agent before surgical method of termination of first-trimester pregnancy

Divya Sinha, Sourabh Shrivastava, Swati Shrivastava

Abstract


Background: Cervical ripening is a critical step for surgical method of termination of first trimester of pregnancy. Misoprostol, PGE1 analogue have promising role as cervical ripening agent. The present study aimed to compare the efficacy and side effects of oral, sublingual and vaginal misoprostol at dosage of 400mcg for cervical priming before surgical method of termination in first-trimester pregnancy.

Methods: It was a prospective hospital based randamosied study. Total 150 patients at 6-12 weeks gestation requesting for medical termination of pregnancy were divided equally in to 3 groups. Every group was advised to have single dose of 400 mcg misoprostol either oral, sublingual or vaginal route respectively 4 hour before suction and evacuation.

Results: The sublingual group had highly significant cervical dilatation (P<0.001) and the duration of suction and evacuation was less as compared to the vaginal and oral routes (p<0.000). However, the mean intraoperative blood loss was more in sublingual as compared to the vaginal and oral groups. Loose motions and nausea/vomiting were more with oral routes while blood loss was more in the vaginal route.

Conclusions: Thus, it can be concluded from present study that sublingual route of misoprostol is more preferable than oral or vaginal route as pro-abortion cervical ripening agent.


Keywords


Cervical ripening, Medical termination of pregnancy. Misoprostol, Surgical method

Full Text:

PDF

References


Creinin MD. Medical management of abortion. American Journal of Obstetrics and Gynecology Practice Bulletin. 2001;26:1-13.

Molin A. Risk of damage to the cervix by dilatation for first trimester- induced abortion by suction aspiration. Gynecol Obstet Invest. 1993;35(3):152-4.

Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988;332:1277-80.

Herting RL, Nissen CH. Overview of misoprostol clinical experience. Dig Dis Sci 1986;31:47S-54S.

Toppozada M, Bygdeman M, Papageorgiou C, Wiqvist N. Administration of 15- methyl-prostaglandin-F2_ as a preoperative means of cervical dilatation. Prostaglandins. 1973;4:371-79.

El-Refaey H, Calder L, Wheatley DN, Templeton A. Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprost. Lancet. 1994;343:1207-09.

Singh K, Fong YF, Prasad RN and Dong F. Randomised trial to determine optimal dose of vaginal misoprostol for preabortion cervical priming. Obstet Gynecol. 1998;92:795-98.

McKinley C, Thong KJ, Baird DT. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod. 1993;8:1502-5.

Tang OS, Miao BY, Lee SW, Ho PC. Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: Efficacy and acceptability. Hum Reprod. 2002;17:654-8.

Saxena P, Sarda N, Salhan S, Nandan D. A randomised comparison between sublingual, oral and vaginal route of misoprostol for pre-abortion cervical ripening in first-trimester pregnancy termination under local anaesthesia. Aust N Z J Obstet Gynaecol. 2008;48:101-6.

Tang OS, Mok KH, Ho PC. A randomized study comparing the use of sublingual to vaginal misoprostol for pre-operative cervical priming prior to surgical termination of pregnancy in the first trimester. Hum Reprod. 2004;19:1101-4.

Tang OS, Miao BY, Lee SW and Ho PC Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod. 2002; 17:332-36.

Saxena P, Salhan S, Sarda N. Comparison between the sublingual and oral route of misoprostol for pre-abortion cervical priming in first trimester abortions. Hum Reprod. 2004;19:77-80.

Tang OS, Lau WN, Ng EH, Lee SW, Ho PC. A prospective randomized study to compare the use of repeated doses of vaginal with sublingual misoprostol in the management of first trimester silent miscarriages. Hum Reprod. 2003;18:176-81.